Medically reviewed by Ritchie Stevens, MD, Radiation Oncologist on June 8, 2026.
_1782506263683-DvIGI5Jo.jpg)
Prostate cancer treatment without surgery - in as few as 5 sessions
The prostate shifts daily — sometimes by more than a centimeter — due to changes in bladder and rectal filling. Conventional radiation treats a fixed plan that can't account for this movement. Adaptive SBRT on the Akesis Gemini 360 re-images and re-plans at every session, placing the dose where the prostate actually is that day.
Prostate cancer treatment options in St. George, Utah
If you have just been diagnosed with localized prostate cancer, you are likely choosing between active surveillance, surgery (radical or robotic prostatectomy), brachytherapy (seed implants), conventional external-beam radiation over 4 to 9 weeks, and stereotactic radiation (SBRT) in 5 sessions.
5D Cancer Services provides the non-surgical option: adaptive SBRT delivered on the Akesis Gemini 360. No incision, no catheter, no hospital stay, no general anesthesia. Most men drive themselves to each appointment and return to normal activity the same day.
The comparison most men care about is surgery versus radiation. Surgery removes the prostate and carries well-documented rates of urinary incontinence and erectile dysfunction in the recovery period. Radiation preserves the prostate and has a different side-effect profile. Neither is universally correct - it depends on your stage, your Gleason score, your PSA, your age, and your priorities. We will tell you honestly if you are a better candidate for something we do not offer.
Why Prostate Cancer needs more than a fixed plan
Prostate cancer radiation requires striking a precise target that refuses to stay still. These are the three anatomy-driven reasons why conventional radiation falls short.
Daily prostate motion
Bladder and rectal filling shift the prostate 5–15 mm between fractions and even within a single session. Conventional plans treat the prostate's average position — not its actual position today.
Large PTV margins = more bowel and bladder dose
To compensate for motion uncertainty, traditional planning adds a large planning target volume (PTV) margin around the prostate. That margin is the rectum, bladder wall, and urethra — and it absorbs full therapeutic dose.
Long courses drift from anatomy
Conventional prostate radiation runs 20–45 fractions over 4–9 weeks. Weight changes, dietary variation, and gradual anatomical shifts compound over that time, eroding the precision the original plan promised.
What the evidence shows
The evidence supporting adaptive SBRT for prostate cancer is among the strongest in radiation oncology. Three pivotal trials establish both safety and superiority over conventional approaches.
PACE-B: 5-fraction SBRT matches long-course IMRT
This international phase 3 randomized trial compared 5-fraction SBRT to 39-fraction IMRT for localized prostate cancer. SBRT was non-inferior for cancer control and produced similar toxicity — establishing ultrahypofractionation as a standard-of-care option for eligible patients.
doi.org/10.1016/S1470-2045(19)30569-8MIRAGE: image guidance cuts acute toxicity by 68%
The MIRAGE randomized trial found that precision image-guided SBRT reduced clinically meaningful acute genitourinary toxicity by 68% compared to CT-guided SBRT. The trial supports the principle that more precise daily targeting directly translates into fewer side effects.
doi.org/10.1001/jamaoncol.2022.6558HYPO-RT-PC: ultra-hypofractionation preserves quality of life at 5 years
The HYPO-RT-PC randomized trial compared ultra-hypofractionated prostate radiation (42.7 Gy in 7 fractions over 2.5 weeks) to conventional fractionation (78 Gy in 39 fractions). Cancer control was non-inferior and patient-reported urinary, bowel, and sexual quality of life were equivalent between arms — establishing ultrahypofractionation as a well-tolerated standard option and validating the direction toward fewer, more precise fractions.
doi.org/10.1016/S1470-2045(19)30813-7Your treatment workflow
At 5D Cancer Services, prostate adaptive SBRT follows a streamlined workflow designed to fit treatment into your schedule with minimal disruption.
Simulation CT (day −7 to −3)
A planning CT is acquired with the patient in treatment position. Bladder and rectal prep instructions are given. The radiation oncologist contours the prostate, seminal vesicles, bladder, rectum, and urethra.
Treatment plan optimization
The medical physics team optimizes an SBRT plan to cover the prostate with high dose while keeping the rectum, bladder wall, and urethra within published tolerance limits.
Daily CBCT imaging and adaptation (sessions 1–5)
Each session begins with a cone-beam CT. The Gemini 360 identifies where the prostate is today, shifts the plan to match, and delivers the adapted beam. Each visit takes approximately 30–45 minutes.
Follow-up (PSA at 3, 6, 12 months, then annually)
PSA is drawn 3 months after the final fraction, then every 6 months for 2 years, then annually. Most patients experience the nadir PSA at 18–36 months post-treatment.
Adaptive vs. conventional radiation
| Factor | Adaptive RT (Gemini 360) | Conventional Radiation |
|---|---|---|
| Total sessions | 5 sessions over 1–2 weeks | 20–45 sessions over 4–9 weeks |
| Daily imaging | CBCT at every session | Periodic or no imaging |
| Plan adaptation | Re-optimized each session | Fixed plan throughout |
| PTV margin | Reduced margins (≤3 mm) | Standard margins (5–10 mm) |
| Rectal dose | Minimized with tight margins | Higher due to larger margins |
| Time off work | Minimal — outpatient, 5 visits | 9 weeks of daily visits |
Frequently asked questions
Is adaptive SBRT appropriate for all prostate cancer stages?
Adaptive SBRT is most commonly used for low-, intermediate-, and high-risk localized prostate cancer. Your radiation oncologist will review your PSA, Gleason score, clinical stage, and imaging to determine whether SBRT or a longer course is the best fit for your specific situation.
What urinary side effects should I expect?
With adaptive SBRT, urinary side effects are typically mild and temporary. Some patients notice increased frequency or mild burning for a few weeks after treatment. Because the Gemini 360 adapts to daily prostate position, the bladder wall receives less radiation than with conventional approaches, reducing both the severity and duration of urinary symptoms.
How does adaptive SBRT compare to prostatectomy (surgery)?
Multiple studies show comparable 10-year cancer control rates between SBRT and radical prostatectomy for localized prostate cancer. SBRT avoids surgery, general anesthesia, hospital stays, and the recovery period associated with surgery. It also carries a lower risk of urinary incontinence. Your treatment team will discuss both options during your consultation.
Will I need hormone therapy alongside radiation?
For low-risk disease, SBRT alone is typically recommended. For intermediate- or high-risk prostate cancer, short-course or long-course androgen deprivation therapy (ADT) added to radiation improves outcomes in most cases. Your radiation oncologist will review the evidence and your specific risk profile to make that recommendation.
Is prostate cancer curable with radiation?
Radiation is a standard-of-care treatment for localized prostate cancer with well-documented long-term cancer control. In the PACE-B randomized trial, 5-fraction SBRT was non-inferior to 39-fraction IMRT for cancer control in eligible patients. Outcomes depend on your stage, Gleason score and PSA - we will review your specific case and give you an honest assessment of what radiation can and cannot achieve.
What are the side effects of prostate radiation - will it affect erections or urination?
The most common short-term effects are urinary urgency and frequency, and some bowel irritation, which usually settle within weeks. Sexual side effects can develop gradually over months to years and vary widely by age and baseline function. Precision matters: the MIRAGE randomized trial found that tighter image guidance reduced clinically meaningful acute urinary toxicity by 68% compared with standard CT-guided SBRT. Daily adaptation on the Gemini 360 is designed to keep dose off the urethra, bladder and rectum.
How much does prostate cancer treatment cost, and does Medicare cover it?
Adaptive radiotherapy is covered by Medicare and Medicaid, as well as Regence Blue Cross Blue Shield, Cigna, Motiv Health, Desert Mutual and University of Utah Health Plans. Our billing team verifies your benefits and handles pre-authorization before treatment starts, so you know your out-of-pocket cost in advance. A shorter course also means fewer copays and fewer trips.
Can I get a second opinion on my prostate cancer treatment plan?
Yes, and no referral is required. Bring your pathology report, PSA history and any imaging, and we will review your case and tell you plainly whether adaptive SBRT is a good fit - including if we think another approach or another center is the better choice. We contact you within one business day of a consultation request.
Educational information — not medical advice
The content on this page is provided for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this site. If you think you may have a medical emergency, call your doctor or 911 immediately.
References
- 1.Brand DH, Tree AC, Ostler P, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019;20(11):1531–1543. doi.org/10.1016/S1470-2045(19)30569-8
- 2.Kishan AU, Ma TM, Lamb JM, et al. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. JAMA Oncol. 2023;9(3):365–373. doi.org/10.1001/jamaoncol.2022.6558
- 3.Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol. 2020;21(3):392–402. doi:10.1016/S1470-2045(19)30813-7 doi.org/10.1016/S1470-2045(19)30813-7
Also see: Adaptive RT by cancer type
Please do not send Protected Health Information (PHI) by email or voicemail. Standard email is not secure — call us and we will arrange a secure channel.
